TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31594032

Group type: EXPERIMENTAL
Intervention: MaxCASTcodes 5 and 6 (dentine and pulpally involved cavities)
Number of subjects: 308

Group type: COMPARATOR
Intervention: MaxCASTcode 3 (enamel carious lesion)
Number of subjects: 308
Study: 29072676

Group type: EXPERIMENTAL
Intervention: Sprinting protocol (gradually increasing spontaneous breathing time off CPAP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non-sprinting protocol (weaning pressure down)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Sprinting protocol
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non-sprinting protocol
Number of subjects: 86
Study: 26864356

Group type: EXPERIMENTAL
Intervention: Whey protein (22 g), essential amino acids (10.9 g, including 4 g leucine), and vitamin D [2.5 μg (100 IU)] with physical activity
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Whey protein, essential amino acids, and vitamin D with physical activity
Number of subjects: 130
Study: 25270680

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg twice daily (BID)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg three times daily (TID)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 22459680

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 20814119

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily for 10 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 14
Study: 17986904

Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate-electrolyte solution (CHO-E)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study: 15580472

Group type: EXPERIMENTAL
Intervention: Combination of continence training (CT) with transanal or perineal electrical stimulation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Physiotherapeutic pelvic floor training alone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Perineal electrical stimulation
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Transanal electrical stimulation
Number of subjects: 180
Study: 12440337

Group type: EXPERIMENTAL
Intervention: Vaginal suppositoria of 100 mg Metronidazole (Arilin rapid) for 2 days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Arilin rapid x 1 glob./2 days followed by vaginal tablets containing lactic acid x 1 glob. for 7 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo therapy (shampoo Dercome Femme containing lactic acid for external application)
Number of subjects: 45
Study: 9505164

Group type: EXPERIMENTAL
Intervention: Formula with 7 g of sugar beet fiber
Number of subjects: 15

Group type: COMPARATOR
Intervention: Formula without sugar beet fiber
Number of subjects: 15
Study: 7872217

Group type: EXPERIMENTAL
Intervention: Caprenin-rich diet (Cap)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Baseline diet enriched in palm oil/palm-kernel oil (PO/PKO)
Number of subjects: 24
Study: 2205342

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors added to digoxin and diuretics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 293141

Group type: EXPERIMENTAL
Intervention: Oral and smoked delta-9-tetrahydrocannabinol (THC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (THC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Plasma THC concentrations < 5.0 ng/mL
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Plasma THC concentrations 5.0 to 10.0 ng/mL
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Plasma THC concentrations > 10.0 ng/mL
Number of subjects: 15
Study: 30861286

Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 61
Study: 30452127

Group type: EXPERIMENTAL
Intervention: Balloon sinus dilation (BSD) plus medical management (MM)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Medical management (MM) alone
Number of subjects: 59
Study: 27973337

Group type: EXPERIMENTAL
Intervention: Pressure-mediated dilatation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intra-arterial administration of nitroglycerine plus verapamil
Number of subjects: 20
Study: 26015372

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham preconditioning
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: RIPC in patients with Mehran risk score ≥11
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham in patients with Mehran risk score ≥11
Number of subjects: 76
Study: 23444283

Group type: EXPERIMENTAL
Intervention: EC‐MPS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MMF
Number of subjects: 27
Study: 21161182

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 19276823

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery with polypectomy
Number of subjects: 27
Study: 17158228

Group type: EXPERIMENTAL
Intervention: Pravastatin (PV) 40‐1680 mg/day, days 1‐8
Number of subjects: 37

Group type: COMPARATOR
Intervention: Idarubicin (Ida) [12 mg/(M2 x day), days 4‐6] + high‐dose cytarabine (Ara‐C; HDAC) [1.5 g/(M2 x day) by CI, days 4‐7]
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pravastatin (PV)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pravastatin (PV) + Idarubicin (Ida) + high-dose cytarabine (Ara-C)
Number of subjects: 37
Study: 15150303

Group type: EXPERIMENTAL
Intervention: IP regimen (continuous portal vein infusion of 5‐fluorouracil at 500 mg/m2 daily for 7 days)
Number of subjects: 1084

Group type: COMPARATOR
Intervention: SY regimen (six 28-day courses of systemic leucovorin at 100 mg/m2 daily on days 1-5 followed by systemic bolus 5‐fluorouracil at 370 mg/m2 daily on days 1-5)
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: IP+SY regimen (IP regimen followed by SY regimen)
Number of subjects: 1084
Study: 11331171

Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pressure stimuli
Number of subjects: 40
Study: 9143014

Group type: EXPERIMENTAL
Intervention: CAG repeat number (39‐56, mean 45.4 +/‐ 4.6)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Morphometric measurements of cross‐sectional areas of the striatum, pallidum, thalamus, amygdala, hippocampus, and cortical grey and white matter
Number of subjects: 23
Study: 7945002

Group type: EXPERIMENTAL
Intervention: Gabapentin therapy
Number of subjects: 25
Study: 2873173

Group type: EXPERIMENTAL
Intervention: Cefotetan 1g iv at induction of anaesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cephazolin iv at induction of anaesthesia
Number of subjects: 100
Study: 29565716

Group type: EXPERIMENTAL
Intervention: Whey protein isolates (40g) plus zinc and selenium
Number of subjects: 42

Group type: COMPARATOR
Intervention: Maltodextrin oral snack
Number of subjects: 42
Study: 27809945

Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate (WPI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Free Amino Acid Mixture (AAM)
Number of subjects: 20
Study: 24234041

Group type: EXPERIMENTAL
Intervention: Pigeons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Humans
Number of subjects: 0
Study: 22092692

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: COMPARATOR
Intervention: Observational group (exclusively breastfed)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Observational group (standard formula-fed)
Number of subjects: 208
Study: 15965213

Group type: EXPERIMENTAL
Intervention: Family support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 0
Study: 12143909

Group type: EXPERIMENTAL
Intervention: Aromatherapy with Melissa essential oil (N = 36)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (sunflower oil) (N = 36)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Aromatherapy with Melissa essential oil
Number of subjects: 72
Study: 9933749

Group type: EXPERIMENTAL
Intervention: Isotretinoin 10 mg/day for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 20
Study: 7501717

Group type: EXPERIMENTAL
Intervention: Sedation with analgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sedation without analgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-controlled medication delivery
Number of subjects: 0
Study: 2305603

Group type: EXPERIMENTAL
Intervention: 300 mg/day ciamexone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 6252466

Group type: EXPERIMENTAL
Intervention: Streptozocin plus fluorouracil
Number of subjects: 84
Study: 30081719

Group type: EXPERIMENTAL
Intervention: Novel fluoride‐containing bioactive glass (QMAT3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sylc glass
Number of subjects: 30

Group type: COMPARATOR
Intervention: Artificial saliva
Number of subjects: 30
Study: 28766537

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with bortezomib for 1 year
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with bortezomib
Number of subjects: 52

Group type: COMPARATOR
Intervention: No maintenance therapy (control group)
Number of subjects: 52
Study: 25568415

Group type: COMPARATOR
Intervention: Kinemax TKA (group 1)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Triathlon TKA (group 2)
Number of subjects: 212
Study: 23696793

Group type: EXPERIMENTAL
Intervention: Doppler-guided prospective ECG gating
Number of subjects: 119

Group type: COMPARATOR
Intervention: Traditional prospective ECG gating
Number of subjects: 119
Study: 21685549

Group type: EXPERIMENTAL
Intervention: stavudine/lamivudine (d4T/3TC)
Number of subjects: 1771

Group type: EXPERIMENTAL
Intervention: didanosine/zidovudine
Number of subjects: 1771
Study: 19085578

Group type: COMPARATOR
Intervention: Indacaterol 100 micro g
Number of subjects: 115

Group type: COMPARATOR
Intervention: Indacaterol 200 micro g
Number of subjects: 115

Group type: COMPARATOR
Intervention: Indacaterol 300 micro g
Number of subjects: 115

Group type: COMPARATOR
Intervention: Indacaterol 400 micro g
Number of subjects: 115

Group type: COMPARATOR
Intervention: Indacaterol 600 micro g
Number of subjects: 115

Group type: COMPARATOR
Intervention: Formoterol 12 micro g twice daily (open-label after washout)
Number of subjects: 115
Study: 16925855

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 2724

Group type: EXPERIMENTAL
Intervention: Sedentary activities
Number of subjects: 2724
Study: 12953180

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50mg zinc gluconate)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11245556

Group type: EXPERIMENTAL
Intervention: Evidence-based clinical guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cochrane systematic reviews
Number of subjects: 0
Study: 9089849

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1590686

Group type: EXPERIMENTAL
Intervention: Rapid infusion of amphotericin B (45 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Slow infusion of amphotericin B (4 h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both infusion rates
Number of subjects: 20
Study: 3703098

Group type: COMPARATOR
Intervention: 0% blood alcohol (control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.05% blood alcohol (ethanol intervention)
Number of subjects: 21
Study: 30232048

Group type: EXPERIMENTAL
Intervention: BGF MDI (budesonide/glycopyrrolate/formoterol fumarate metered‐dose inhaler 320/18/9·6 μg)
Number of subjects: 1902

Group type: EXPERIMENTAL
Intervention: BGF MDI
Number of subjects: 1902

Group type: COMPARATOR
Intervention: GFF MDI (glycopyrrolate/formoterol fumarate metered‐dose inhaler 18/9·6 μg)
Number of subjects: 1902

Group type: COMPARATOR
Intervention: BFF MDI (budesonide/formoterol fumarate metered‐dose inhaler 320/9·6 μg)
Number of subjects: 1902

Group type: COMPARATOR
Intervention: BUD/FORM DPI (budesonide/formoterol fumarate dry‐powder inhaler 400/12 μg)
Number of subjects: 1902
Study: 27111751

Group type: EXPERIMENTAL
Intervention: STEPS‐UP (stepped, centrally assisted collaborative care model)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Usual collaborative care (control)
Number of subjects: 666
Study: 25487708

Group type: EXPERIMENTAL
Intervention: SIRT + mFOLFOX6 (with a reduced dose of oxaliplatin in cycles 1-3 following SIRT)
Number of subjects: 450

Group type: COMPARATOR
Intervention: mFOLFOX6
Number of subjects: 450
Study: 23265037

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg orally one hour before surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 44
Study: 20658007

Group type: EXPERIMENTAL
Intervention: Epley maneuver associated with the use of neck collar and post‐maneuver instructions
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Epley maneuver without the use of cervical collar and/or post‐maneuver restrictions
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Epley maneuver associated with the use of a mini vibrator, without the use of neck collar and/or post‐maneuver restrictions
Number of subjects: 53
Study: 18503906

Group type: EXPERIMENTAL
Intervention: Alteplase (2 mg or 4 mg based on infusion volumes of 0-50 mL or 51-100 mL, administered twice daily for 3 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline solution (administered twice daily for 3 days)
Number of subjects: 20
Study: 15922697

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once nightly)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Fluticasone (88 mug twice daily)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fluticasone and Montelukast
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 400
Study: 12782903

Group type: EXPERIMENTAL
Intervention: Combined-strength and aerobic exercise program (2 strength sessions at 60% of 1 repetition maximum and 2 aerobic sessions at 60%-85% of maximum heart rate) for 8 months
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combined-strength and aerobic exercise program (2 strength sessions at 60% of 1 repetition maximum and 2 aerobic sessions at 60%-85% of maximum heart rate) for 8 months followed by 3 months of detraining
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study: 10227569

Group type: EXPERIMENTAL
Intervention: Nondiabetic siblings who perceived themselves at increased risk of diabetes
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Nondiabetic siblings who thought diabetes was a serious problem
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Factors predicting perceptions of diabetes risk
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Factors predicting increased likelihood perception
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Perception of vulnerability to diabetes
Number of subjects: 540
Study: 8546909

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1 intravenously (i.v.) on day 1, dexamethasone 20 mg i.v. on days 2 and 3 and prochlorperazine 5 mg orally thrice daily on days 1‐5
Number of subjects: 70

Group type: COMPARATOR
Intervention: Granisetron 40 micrograms kg‐1 i.v. on day 1 alone
Number of subjects: 70
Study: 1890517

Group type: EXPERIMENTAL
Intervention: Rectal ketamine (5 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rectal midazolam (0.30 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (0.05 mg/kg) after induction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60
Study: 6120350

Group type: EXPERIMENTAL
Intervention: Etretinate ('Tigason')
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31661431

Group type: EXPERIMENTAL
Intervention: DELTA2 recommendations for choosing the target difference in sample size calculations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 28964591

Group type: EXPERIMENTAL
Intervention: Trofinetide 35 mg/kg twice daily for 14 days
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Trofinetide 35 mg/kg twice daily for 28 days
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Trofinetide 70 mg/kg twice daily for 28 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 25562205

Group type: EXPERIMENTAL
Intervention: Cariprazine 3-6 mg/d
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Cariprazine 6-12 mg/d
Number of subjects: 497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study: 24227821

Group type: EXPERIMENTAL
Intervention: Individualized prophylaxis (25‐65 IU/kg every 3‐5 days, n = 118)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Weekly prophylaxis (65 IU/kg, n = 24)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Episodic treatment (10‐50 IU/kg, n = 23)
Number of subjects: 165

Group type: COMPARATOR
Intervention: rFVIIIFc
Number of subjects: 165
Study: 23142049

Group type: EXPERIMENTAL
Intervention: Selective anteromedial (AM) bundle reconstruction
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard anatomic single-bundle reconstruction
Number of subjects: 54
Study: 19403640

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate
Number of subjects: 235

Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 235
Study: 18163065

Group type: EXPERIMENTAL
Intervention: Moving pulse magnetic field (MPMF) treatment
Number of subjects: 145

Group type: COMPARATOR
Intervention: Traditional physical methods
Number of subjects: 145
Study: 15132444

Group type: EXPERIMENTAL
Intervention: Fan-type rapid maxillary expansion (RME)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 11817775

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (150 mg/day)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Plain aspirin (150 mg/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 47
Study: 9536226

Group type: EXPERIMENTAL
Intervention: Calcipotriene ointment 0.005%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 30
Study: 7662599

Group type: EXPERIMENTAL
Intervention: Controlled-delivery diltiazem 180 mg qd
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled-delivery diltiazem 360 mg qd
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release diltiazem 60 mg tid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate-release diltiazem 120 mg tid
Number of subjects: 0
Study: 2678881

Group type: EXPERIMENTAL
Intervention: Cytobrush
Number of subjects: 126

Group type: COMPARATOR
Intervention: ENT-swabs
Number of subjects: 126

Group type: COMPARATOR
Intervention: White, cotton-tipped swabs
Number of subjects: 126

Group type: COMPARATOR
Intervention: Pathologic wet smear
Number of subjects: 126
Study: 1180955

Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 tablets 0.5 mg hourly
Number of subjects: 106

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 tablets
Number of subjects: 106
Study: 31666302

Group type: EXPERIMENTAL
Intervention: Slow method of tenaculum placement (closure over a 5‐s period)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cough method of tenaculum placement (closure at the time of patient's cough)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Overall pain scores
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Provider satisfaction
Number of subjects: 66
Study: 30454671

Group type: EXPERIMENTAL
Intervention: Counseling plus patches
Number of subjects: 4268696

Group type: EXPERIMENTAL
Intervention: Counseling plus gift card
Number of subjects: 4268696

Group type: EXPERIMENTAL
Intervention: Counseling plus patches and gift card
Number of subjects: 4268696

Group type: COMPARATOR
Intervention: Counseling only
Number of subjects: 4268696
Study: 27321097

Group type: EXPERIMENTAL
Intervention: Flexible GnRH antagonist protocol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Long GnRH agonist protocol
Number of subjects: 90
Study: 24571886

Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol fixed combination (0.03% bimatoprost and 0.5% timolol, once daily at 19:00 P.M.)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Concurrent treatment (0.03% bimatoprost followed by 0.5% timolol, once daily at 19:00 P.M.)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol fixed combination
Number of subjects: 235

Group type: COMPARATOR
Intervention: Concurrent treatment
Number of subjects: 235
Study: 22429099

Group type: EXPERIMENTAL
Intervention: Inpatient geriatric consultation teams (IGCTs)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 171
Study: 19622117

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/day
Number of subjects: 709

Group type: COMPARATOR
Intervention: Lamivudine 100 mg/day
Number of subjects: 709
Study: 18614945

Group type: EXPERIMENTAL
Intervention: Beta-glucan (5.6 g x d(‐1))
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15728041

Group type: EXPERIMENTAL
Intervention: Deltoid tuberosity landmark
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 60
Study: 11354578

Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TMR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical treatment alone (Control)
Number of subjects: 100
Study: 9330152

Group type: EXPERIMENTAL
Intervention: Single-injection transthecal digital block technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single-injection subcutaneous technique
Number of subjects: 20
Study: 8198024

Group type: EXPERIMENTAL
Intervention: Fluvastatin therapy
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Cholestyramine, 8 g/day
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429